

## New Horizon develops technology partnership with Prenetics

23 October 2019 | News

### New Horizon will provide a technical transfer to Prenetics for ColoClear



China's leading non-invasive colon cancer screening biotech company, New Horizon Health Limited, announced in a signing ceremony that it had entered into an exclusive agreement with Prenetics Limited, a leading genetics and digital health company in Asia and Europe.

Under the terms of the agreement, New Horizon will provide a technical transfer to Prenetics for ColoClear. ColoClear, a non-invasive multi-target stool DNA test for colorectal cancer, has been specifically developed for individuals whom are of Asian ethnicity and have been validated through clinical studies to perform at 92% sensitivity in the detection of colon cancer.

In addition, the agreement calls for that Prenetics will set up a dedicated facility in its ISO-15189 accredited Hong Kong laboratory to begin commercialization services for Hong Kong in early 2020 and for Southeast Asia later in the year.

Yeqing Zhu, CEO of New Horizon, stated, "Since company inception in 2013, our mission is to make our technology available to as many people as possible throughout Asia in the fight against Colon Cancer. With ColoClear, we have now validated through multi-center clinical studies that it is the leading non-invasive colon cancer stool DNA test in the market here in Asia. We are extremely excited to partner with Prenetics for the technical transfer and commercialization of ColoClear in Hong Kong and for Southeast Asia."

Danny Yeung, CEO of Prenetics, stated, "Colon Cancer is one of the most common cancers in Hong Kong and in Southeast Asia. It is also most often diagnosed at too late of a stage and one which is highly preventable with early detection. With ColoClear, it is a true technological Game Changer in terms of performance and can be accessible by millions of people in the region. Through our initial market research, we have already received immensely positive responses from Insurers, clinics, hospitals, and consumers on ColoClear. Together with New Horizon, we look to significantly reduce both the mortality and incidence rate of Colon Cancer in the region."

ColoClear is backed by strong science and robust clinical research. ColoClear is a non-invasive screening test for individuals

who are at risk of developing colon cancer.